<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
  <title>Linux Format forums</title>
  <link>http://www.linuxformat.com/forums/index.php</link>
  <description>Help, discussion, magazine feedback and more</description>
  <language>english</language>
  <copyright>(c) Copyright Sun May 19, 2013 3:46 am by Linux Format forums</copyright>
  <managingEditor>webmaster@linuxformat.com</managingEditor>
  <webMaster>webmaster@linuxformat.com</webMaster>
  <pubDate>Sun May 19, 2013 3:46 am</pubDate>
  <lastBuildDate>Sun May 19, 2013 3:46 am</lastBuildDate>
  <docs>http://backend.userland.com/rss</docs>
  <generator>phpBB2 RSS Syndication Mod by Lucas</generator>
  <ttl>1</ttl>

  <image>
    <title>Linux Format forums</title>
    <url></url>
    <link>http://www.linuxformat.com/forums/</link>
    <description>Help, discussion, magazine feedback and more</description>
  </image>

                                      <item>
                                        <title>Novartis: (Software patents == Pharmaceutical patents) ?</title>
                                        <link>http://www.linuxformat.com/forums/viewtopic.php?p=35044#35044</link>
                                        <description>&lt;br /&gt;
                                      Author: &lt;a href='http://www.linuxformat.com/forums/profile.php?mode=viewprofile&amp;u=541'&gt;hubris&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;
                                      Posted: Fri Dec 01, 2006 1:10 pm&lt;br /&gt;&lt;br /&gt;
                                      &lt;br /&gt;&lt;br /&gt;
                                      Novartis is a pharmaceautical company behind the anti-cancer drug Glivec. India has stopped Novartis' application for a patent for this drug, allowing other pharmaceuticals in India to provide generic versions of it. However, Novartis is currently challenging this.&lt;br /&gt;
&lt;br /&gt;
The details are available here:&lt;br /&gt;
&lt;a href=&quot;http://www.oxfam.org.uk/what_you_can_do/campaign/mtf/a2m_faq.htm&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;http://www.oxfam.org.uk/what_you_can_do/campaign/mtf/a2m_faq.htm&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;
I sent an email to Novartis via Oxfam earlier this month. And received a response from Novartis yesterday. The response is available here:&lt;br /&gt;
&lt;a href=&quot;http://www.novartis.com/responses/Novartis_response-Oxfam_trade_campaign.pdf&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;http://www.novartis.com/responses/Novartis_response-Oxfam_trade_campaign.pdf&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;
Is somebody able to help me write a response to Novartis? In particular, I'm trying to tie in patents with the European software patents directive that was the hot topic about a year ago. In software patents, I understand that it was the process, and not necessarily the implementation that patent supporters wanted patentable. Are arguments for open-source (unpatented) software equally (or at all) applicable to medicines, and should they be? The crux of this in Novartis' response is &quot;The best way to encourage innovation is via respect for intellectual property&quot;.&lt;br /&gt;
&lt;br /&gt;
Many thanks.</description>
                                        <comments>http://www.linuxformat.com/forums/viewtopic.php?p=35044#35044</comments>
                                        <author>hubris</author>
                                        <pubDate>Fri Dec 01, 2006 1:10 pm</pubDate>
                                        <guid isPermaLink="true">http://www.linuxformat.com/forums/viewtopic.php?p=35044#35044</guid>
                                      </item></channel></rss>